Yazdan Yazdanpanah to Antiviral Agents
This is a "connection" page, showing publications Yazdan Yazdanpanah has written about Antiviral Agents.
Connection Strength
0.329
-
Nebulised interferon beta-1a for patients with COVID-19. Lancet Respir Med. 2021 02; 9(2):122-123.
Score: 0.084
-
Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France. J Viral Hepat. 2018 10; 25(10):1197-1207.
Score: 0.071
-
[Antiretroviral drugs in severe acute respiratory syndrome]. Presse Med. 2006 Jan; 35(1 Pt 2):105-7.
Score: 0.030
-
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021 08 19; 13(8).
Score: 0.022
-
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec; 27(12):1826-1837.
Score: 0.022
-
Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. Cell Rep Med. 2020 07 21; 1(4):100059.
Score: 0.021
-
Review of trials currently testing treatment and prevention of COVID-19. Clin Microbiol Infect. 2020 Aug; 26(8):988-998.
Score: 0.020
-
Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020 06; 178:104791.
Score: 0.020
-
Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018 03; 25 Suppl 1:6-17.
Score: 0.017
-
The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis. 2017 02 21; 17(1):162.
Score: 0.016
-
Case report study of the first five COVID-19 patients treated with remdesivir in France. Int J Infect Dis. 2020 Sep; 98:290-293.
Score: 0.005